Cancer / Tumor Profiling

Cancer / Tumor Profiling

Global Cancer / Tumor Profiling Market to Reach US$19.8 Billion by 2030

The global market for Cancer / Tumor Profiling estimated at US$10.3 Billion in the year 2023, is expected to reach US$19.8 Billion by 2030, growing at a CAGR of 9.8% over the analysis period 2023-2030. Immunoassays Technology, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$6.2 Billion by the end of the analysis period. Growth in the Next Generation Sequencing Technology segment is estimated at 10.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.7 Billion While China is Forecast to Grow at 10.6% CAGR

The Cancer / Tumor Profiling market in the U.S. is estimated at US$3.7 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 10.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.7% and 9.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.9% CAGR.

Global Cancer / Tumor Profiling Market - Key Trends & Drivers Summarized

The advent of molecular profiling, driven by genomics and next-generation sequencing (NGS), is revolutionizing personalized cancer treatment. By using tissue samples and less invasive liquid biopsies, molecular profiling identifies genetic mutations and fusions that are crucial for personalized cancer therapies. In recent years, the application of DNA/RNA sequencing on formalin-fixed, paraffin-embedded (FFPE) tissues significantly enhanced the ability to pinpoint actionable targets within tumors. Nevertheless, having a druggable target does not necessarily ensure its role in disease progression or clinical efficacy. Effective molecular profiling necessitates advanced technical skills and a profound understanding of tumor biology and associated therapies, especially in cases lacking standardized treatments where NGS provides alternative therapeutic options.

Tumor profiling offers comprehensive insights into the genetic landscape of cancers, facilitating the development of targeted therapies aimed at specific genetic alterations. This approach notably transformed the treatment of lung cancer, with therapies targeting EGFR mutations being among the earliest successful examples. Beyond pinpointing individual mutations, profiling elucidates the broader molecular framework of cancer progression and resistance mechanisms, paving the way for combination therapies to combat resistance. Additionally, the identification of biomarkers through profiling can predict patient responses to immunotherapy, enabling more personalized treatment regimens. The integration of liquid biopsy techniques, such as ctDNA and CTC analysis, further augments profiling capabilities, allowing non-invasive, real-time monitoring of tumor dynamics and minimal residual disease.

The growth in the cancer/tumor profiling market is driven by several factors, including advancements in molecular profiling technologies, increased adoption of liquid biopsies, and the integration of AI and machine learning. The development of single-cell sequencing technologies offers granular insights into tumor heterogeneity, identifying subpopulations driving disease progression and therapy resistance. This level of detail supports the creation of more effective treatment strategies. Moreover, AI and ML enhance the analysis of complex molecular data, improving the accuracy of profiling and enabling the prediction of patient outcomes. The expanding capabilities of these technologies, combined with their integration into clinical practice, promise more personalized and responsive cancer treatments, ultimately leading to better patient outcomes and continuous innovation in oncology.

Select Competitors (Total 55 Featured) -

• Caris Life Sciences
• Genomic Health, Inc.
• Helomics Corporation
• HTG Molecular Diagnostics, Inc.
• Illumina, Inc.
• Nanostring Technologies, Inc.
• NeoGenomics Laboratories, Inc.
• Oxford Gene Technology
• Qiagen NV
• Ribomed Biotechnologies, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.